文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

COVID-19与非COVID-19危重症幸存者6个月结局比较

Comparison of 6-Month Outcomes of Survivors of COVID-19 versus Non-COVID-19 Critical Illness.
PubMed 文献 · Am J Respir Crit Care Med · 2022-01-01
一句话结论机械通气≥24小时的COVID-19幸存者与非COVID-19危重症幸存者6个月新发残疾无差异,180天死亡率亦相似。

该研究纳入两项前瞻性观察性研究中的机械通气≥24小时成人患者,比较COVID-19与非COVID-19危重症幸存者6个月结局。COVID-19患者年龄更大、APACHE II评分更低、通气时间更长,但180天死亡率相似(32.5% vs 35.2%,P=0.715),死亡或新发残疾复合终点亦相似(62.4% vs 66.0%,P=0.583)。结论提示COVID-19与非COVID-19急性呼吸衰竭机械通气患者6个月新发残疾无差异。

要点

  • COVID-19组180天死亡39/120(32.5%),非COVID-19组70/199(35.2%),P=0.715,两组死亡率相似。
  • COVID-19组死亡或新发残疾58/93(62.4%),非COVID-19组99/150(66.0%),P=0.583,无差异。
  • COVID-19组通气时间12(5-19)天,非COVID-19组4.8(2.3-8.8)天,P<0.001,COVID-19组更长。
  • COVID-19组年龄62(55-71)岁,非COVID-19组58(44-69)岁,P=0.019;APACHE II评分17(13-20) vs 19(15-23),P=0.011。
  • 6个月新发残疾用WHODAS 2.0电话评估,两组无差异。

适用人群与场景

  • 成人(年龄≥18岁)机械通气≥24小时的危重症患者;COVID-19患者需SARS-CoV-2 PCR检测阳性。
  • 来自澳大利亚ICU的两项前瞻性观察性研究:COVID-19患者2020年3月6日至2021年4月21日,非COVID-19患者2017年8月至2019年1月。

诊断标准与关键阈值

  • COVID-19纳入需SARS-CoV-2 PCR检测阳性;两组均需机械通气≥24小时。
  • 新发残疾采用世界卫生组织残疾评估量表2.0(WHODAS 2.0)电话评估。

研究设计与关键结果

  • 研究类型:两项前瞻性观察性研究;样本量:COVID-19组120例,非COVID-19组199例;人群:澳大利亚ICU机械通气≥24小时成人。
  • COVID-19组年龄62(55-71)岁 vs 非COVID-19组58(44-69)岁,P=0.019;APACHE II评分17(13-20) vs 19(15-23),P=0.011。
  • 通气时间COVID-19组12(5-19)天 vs 非COVID-19组4.8(2.3-8.8)天,P<0.001。
  • 180天死亡率COVID-19组39/120(32.5%) vs 非COVID-19组70/199(35.2%),P=0.715。
  • 180天死亡或新发残疾COVID-19组58/93(62.4%) vs 非COVID-19组99/150(66.0%),P=0.583。

证据类型、等级与局限

  • 证据类型:前瞻性观察性研究;临床试验注册号NCT04401254。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文结论:COVID-19所致急性呼吸衰竭机械通气患者与非COVID-19患者6个月新发残疾无差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Rationale: The outcomes of survivors of critical illness due to coronavirus disease (COVID-19) compared with non-COVID-19 are yet to be established. Objectives: We aimed to investigate new disability at 6 months in mechanically ventilated patients admitted to Australian ICUs with COVID-19 compared with non-COVID-19. Methods: We included critically ill patients with COVID-19 and non-COVID-19 from two prospective observational studies. Patients were eligible if they were adult (age ⩾ 8 yr) and received ⩾24 hours of mechanical ventilation. In addition, patients with COVID-19 were eligible with a positive laboratory PCR test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Measurements and Main Results: Demographic, intervention, and hospital outcome data were obtained from electronic medical records. Survivors were contacted by telephone for functional outcomes with trained outcome assessors using the World Health Organization Disability Assessment Schedule 2.0. Between March 6, 2020, and April 21, 2021, 120 critically ill patients with COVID-19, and between August 2017 and January 2019, 199 critically ill patients without COVID-19, fulfilled the inclusion criteria. Patients with COVID-19 were older (median [interquartile range], 62 [55-71] vs. 58 [44-69] yr; P = 0.019) with a lower Acute Physiology and Chronic Health Evaluation II score (17 [13-20] vs. 19 [15-23]; P = 0.011). Although duration of ventilation was longer in patients with COVID-19 than in those without COVID-19 (12 [5-19] vs. 4.8 [2.3-8.8] d; P < 0.001), 180-day mortality was similar between the groups (39/120 [32.5%] vs. 70/199 [35.2%]; P = 0.715). The incidence of death or new disability at 180 days was similar (58/93 [62.4%] vs. 99/150 [66/0%]; P = 0.583). Conclusions: At 6 months, there was no difference in new disability for patients requiring mechanical ventilation for acute respiratory failure due to COVID-19 compared with non-COVID-19. Clinical trial registered with www.clinicaltrials.gov (NCT04401254).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Hodgson CL, Higgins AM, Bailey MJ, et al. Comparison of 6-Month Outcomes of Survivors of COVID-19 versus Non-COVID-19 Critical Illness. Am J Respir Crit Care Med. 2022. PMID: 35258437. doi:10.1164/rccm.202110-2335OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。